TCON Insider Trading Activity and SEC Form 4 Filings
TCON insider trading summary
No open-market insider purchases or sales of Tracon Pharmaceuticals, Inc. (TCON) have been reported on SEC Form 4 in the past 12 months.
Latest TCON insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 10, 2023 | Opaleye Management Inc. | 10% Owner | Sell | $129K (440,000 @ $0.29) |
| Nov 10, 2023 | Opaleye Management Inc. | 10% Owner | Sell | $1.3M (4,324,008 @ $0.29) |
| Apr 27, 2023 | Charles Theuer | President and CEO | Buy | $35K (47,000 @ $0.75) |
| Apr 26, 2023 | Charles Theuer | President and CEO | Buy | $3K (3,999 @ $0.66) |
| Mar 9, 2023 | Opaleye Management Inc. | 10% Owner | Buy | $241K (174,508 @ $1.38) |
| Mar 1, 2023 | Charles Theuer | President and CEO | Buy | $7K (4,800 @ $1.52) |
| Feb 28, 2023 | Charles Theuer | President and CEO | Buy | $304 (200 @ $1.52) |
| Jan 18, 2023 | Charles Theuer | President and CEO | Buy | $11K (6,800 @ $1.62) |
| Dec 29, 2022 | Scott B. Brown | Chief Financial Officer | Buy | $5K (3,500 @ $1.49) |
| Dec 21, 2022 | William R Larue | Director | Sell | $151 (120 @ $1.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.